Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Price: $28.29 -0.04%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold with a price target of $25 on of Allergan takeover.
"We’re still surprised by the timing though more may be known when filings come out. At this point we think the deal price is reasonable and for MAPP shareholders it eliminates FDA risk assuming a pre-PDUFA closing (April 15) and in our view for AGN
makes another bidder unlikely."
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.71 yesterday.
"We’re still surprised by the timing though more may be known when filings come out. At this point we think the deal price is reasonable and for MAPP shareholders it eliminates FDA risk assuming a pre-PDUFA closing (April 15) and in our view for AGN
makes another bidder unlikely."
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
- Curaleaf announces unsolicited takeover bid for Aurora Cannabis
Create E-mail Alert Related Categories
DowngradesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
